Price corridors require consolidated transaction evidence

Prices were defensible individually and incomparable in aggregate

The engagement addressed pricing consistency across global markets. The obstacle was not a deficit of pricing capability. Pricing practices were fragmented across 100+ countries and multiple ERP systems, which produced inconsistent price levels and limited insight into true deal profitability. Manual consolidation of the data required weeks of effort.

This is the central finding: each price was defensible in the market where it was set, and no price was comparable with any other. The exposure takes three forms, continuing margin leakage, misaligned regional strategies, and slower decision-making in competitive bids.

The comparison is nobody's remit, and the team it belongs to was assembling data by hand

An €18B healthcare technology business employs commercial excellence specialists, regional pricing managers and finance controllers who understand its products, its channels and its tender dynamics better than an external team will. This article does not claim otherwise. The constraint was structural.

Transaction data sat in multiple ERP systems across 100+ countries, under product hierarchies, discount structures and unit conventions defined region by region. Rendering it comparable is a precondition of analysis rather than an instance of it, and no regional unit holds the standing to impose a common structure on its peers. The one team whose remit covered the comparison was spending its weeks assembling the view by hand, so a contested price was determined by seniority rather than by evidence. The consolidation was the constraint.

Pricing moved from precedent to evidence

What that enables. A proposed price is tested against a defined corridor rather than against precedent, and a unit that prices outside it argues the case on the transaction evidence. No unit has to agree with the corridor. Every unit has to price against the same one.

One figure is published, one is left out

One figure is published here, with the qualification the record carries. €30M annual margin improvement potential. It denotes potential, not margin banked.

One figure is left out. The record states a 3x faster pricing cycle, supported by the statement that automated consolidation reduced manual review time from weeks to days. The multiplier carries no qualifier, the verb asserts that the reduction was delivered, and weeks against days is directional rather than measured. An 8 to 10 week sprint that built the instrument did not observe a year of cycles on it.

Source. Every figure here comes from the SprintlyWorks engagement record for Building a Global Pricing Framework, a €18B global healthcare technology company, October 2025. Clients are described, never named. Where a figure is identified or modelled rather than banked, this article says so. The record carries no client statement, so the concession above is made in our voice.

Buy the first consolidation, then own the instrument

We place one senior analyst and two analysts on one defined question for 8 to 10 weeks. The client receives the fieldwork, the analysis and the handover, and retains the instrument, so the second reading is its own team's work. After the handover the case for external help recedes.

If prices in your business are defensible one deal at a time and indefensible in aggregate, that is the shape of problem this sprint addresses.

Write to rahul.abhisek@sprintlyworks.com and we will tell you on the first call whether it is worth the time. If a sprint is the wrong instrument, we will say so instead.